US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

China Pharma Holdings Inc

us-stock
To Invest in {{usstockname}}
us-stock
$1.8 -0.0196(-1.96%) CPHI at 04 Dec 2025 04:28 PM Drug Manufacturers - Specialty & Generic
Lowest Today 1.8
Highest Today 1.8
Today’s Open 1.8
Prev. Close 1.836
52 Week High 3.35
52 Week Low 1.20
Day’s Range: Low 1.8 High 1.8
52-Week Range: Low 1.20 High 3.35
1 day return -
1 Week return -
1 month return +21.05
3 month return +3.95
6 month return +8.87
1 year return +843.58
3 year return -77.29
5 year return -91.95
10 year return -

Institutional Holdings

Market Status

Fundamentals

Market Cap 4.96 M

PB Ratio 0.9665

PE Ratio 0.0

Enterprise Value 11.34 M

Total Assets 14.89 M

Volume 2574

Company Financials

Annual Revenue FY23:7782613 7.8M, FY22:8104092 8.1M, FY21:9641925 9.6M, FY20:10866449 10.9M, FY19:10923936 10.9M

Annual Profit FY23:-159245 -0.2M, FY22:-493916 -0.5M, FY21:349270 0.3M, FY20:1952906 2.0M, FY19:1482184 1.5M

Annual Net worth FY23:-3110789 -3.1M, FY22:-10221635 -10.2M, FY21:-3941477 -3.9M, FY20:-3160936 -3.2M, FY19:-21023762 -21.0M

Quarterly Revenue Q3/2025:756217000000 756217.0M, Q2/2025:1025767 1.0M, Q1/2025:1136287 1.1M, Q3/2024:1100152 1.1M, Q2/2024:924943 0.9M

Quarterly Profit Q3/2025:-59654000000 -59654.0M, Q2/2025:-87010 -0.1M, Q1/2025:-136061 -0.1M, Q3/2024:-519649 -0.5M, Q2/2024:-1120308 -1.1M

Quarterly Net worth Q3/2025:-651482000000 -651482.0M, Q2/2025:-528367 -0.5M, Q1/2025:-785572 -0.8M, Q3/2024:-1117911 -1.1M, Q2/2024:-1438130 -1.4M

Fund house & investment objective

Company Information China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets. It offers Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.

Organisation Drug Manufacturers - Specialty & Generic

Employees 224

Industry Drug Manufacturers - Specialty & Generic

CEO Ms. Zhilin Li

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right